1 / 26

Status epilepticus

Status epilepticus. Status Epilepticus. Traditionally, SE is defined as continuous or repetitive seizure activity persisting for at least 30 minutes without recovery of consciousness between attacks.

zeroun
Télécharger la présentation

Status epilepticus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Status epilepticus

  2. Status Epilepticus • Traditionally, SE is defined as continuous or repetitive seizure activity persisting for at least 30 minutes without recovery of consciousness between attacks. • For all practical purposes, a patient should be considered to be in SE if a seizure persists for more than 5 minutes.

  3. Status Epilepticus

  4. Epidemiology and Risk Factor • 100,000 to 150,000 patients per year in the United States are diagnosed with SE. • Approximately one half of the cases occur in young children, but the risk in adults older than 60 years of age is high. • The published incidence of SE usually under estimate NCSE.

  5. Status epilepticus occurs in :

  6. Etiology of status epilepticus in adult

  7. Status epilepticus in pediatrics • Convulsive status epilepticus is the most common neurological emergency in childhood. • Prolonged febrile sizeurs is the most common cause. • Low morbidity and mortality . • The general principle of management is the same as adult.

  8. Causes of first episode of convulsive status epilepticus in children

  9. Management of SE • Rapidity of treatment is important. • Therapeutic intervention are most effective when started early and efficacy decrease significantly with increasing seizures duration. • Initial step include basic life support , focused history , initiating IV access , laboratory studies and benzodiazepine.

  10. Refractory status epilepticus • CIV pentobarbital. Load: 5 mg/kg at up to 50 mg/min; repeat 5 mg/kg boluses until seizures stop. Initial CIV rate: 1 mg/kg/h. CIV dose range: 0.5 mg/kg/h to 10 mg/kg/h. • traditionally titrated to suppression burst on EEG but titrating to seizure suppression is reasonable as well.

  11. Parmacotheray for treatment of status Epilepticus

  12. Parmacotheray for treatment of status Epilepticus

  13. Parmacotheray for treatment of status Epilepticus

  14. Parmacotheray for treatment of status Epilepticus

  15. Parmacotheray for treatment of status Epilepticus

  16. Parmacotheray for treatment of status Epilepticus

  17. Parmacotheray for treatment of status Epilepticus

  18. EEG monitoring • EEG is mandatory for correct diagnosis and monitoring response to therapy. • Residual electrical seizure activity occur almost in 50% of patient who present with GCSE after cessation of motor activity. • Persistent NCSE can prevent recovery and add to morbidty.

  19. Complication of SE • Hippocampal complex , amygedla , thalmus are vulnerable to SE which lead to permanent impairment in memory , affect and cognetion. • Mortality range between 3% to 20% , children have lower mortality rate than adult.

  20. Future Directions • IV lorezpam is an excellent first line treatment but step after that are less clear and require and require randomized trials. • Neuroprotection is a new focus for research , some newer AEDs have neuroprotictive property that may prevent neuronal injury ,other neuroprotictive methods are hypothetmia , antioxidants and erythropoietin.

  21. Future Directions • Development of reliable neuronal injury marker will be quite helpful in determining which patient require aggressive treatment and to predict outcome. • Neuron specific enolase which is elevated in patient with SE and correlate with duration and outcome is under investigation to be used as a marker.

  22. Thank you Hind Alnajashi

More Related